US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Niagen Bioscience

8.95

-0.2900-3.14%

Post-market: 8.960.0100+0.11%19:57 EDT

Volume:1.32M

Turnover:11.80M

Market Cap:704.08M

PE:81.36

High:9.31

Open:9.22

Low:8.72

Close:9.24

Loading ...

Overview Company News Filings

Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary

Stock Track | Niagen Bioscience (NAGE) Soars 6.39% After-Hours on Strong Q1 Earnings, Raised Outlook

Stock Track | Niagen Bioscience Soars 6.39% After Hours on Strong Q1 Results and Raised 2025 Outlook

Niagen Bioscience Q1 EPS $0.06 Beats $0.02 Estimate, Sales $30.48M Beat $27.10M Estimate

Niagen Bioscience Inc Outlook 2025 Company Expects Between 20% to 25% Year-Over-Year Revenue Growth

THOMSON REUTERS

Press Release: Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

Niagen Bioscience Inc expected to post earnings of 2 cents a share - Earnings Preview

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

Three High Growth Companies Insiders Are Eager To Hold

Simply Wall St.

BRIEF-Niagen Bioscience Welcomes Pinchas Cohen To Scientific Advisory Board

Niagen Bioscience Welcomes DR. Pinchas Cohen to Scientific Advisory Board

THOMSON REUTERS

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Press Release: Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Niagen Bioscience Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

BRIEF-Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

THOMSON REUTERS

Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments

MT Newswires Live

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

THOMSON REUTERS

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Growth Companies With High Insider Ownership For April 2025

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NAGE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":8.95,"timestamp":1746820800000,"preClose":9.24,"halted":0,"volume":1318957,"hourTrading":{"tag":"盘后","latestPrice":8.96,"preClose":8.95,"latestTime":"19:57 EDT","volume":9031,"amount":80561.7922,"timestamp":1746835030418},"delay":0,"floatShares":50773135,"shares":78668309,"eps":0.11,"marketStatus":"Market Closed","change":-0.29,"latestTime":"05-09 16:00:00 EDT","open":9.22,"high":9.31,"low":8.72,"amount":11803864.543101,"amplitude":0.063853,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.11,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":9.24,"preHourTrading":{"tag":"盘前","latestPrice":9.37,"preClose":9.24,"latestTime":"09:14 EDT","volume":11242,"amount":105316.933414,"timestamp":1746796449113},"postHourTrading":{"tag":"盘后","latestPrice":8.96,"preClose":8.95,"latestTime":"19:57 EDT","volume":9031,"amount":80561.7922,"timestamp":1746835030418},"volumeRatio":0.7972280221812981,"impliedVol":1.1602,"impliedVolPercentile":0.6757},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","floatShares":50773135,"roa":"12.21%","roe":"33.47%","lyrEps":0.112605,"volumeRatio":0.7972280221812981,"shares":78668309,"dividePrice":0,"high":9.31,"amplitude":0.063853,"preClose":9.24,"low":8.72,"week52Low":2.305,"pbRate":"12.72","psRate":"6.52","week52High":9.5,"institutionHeld":0,"latestPrice":8.95,"eps":0.11,"divideRate":0,"volume":1318957,"delay":0,"ttmEps":0.11,"open":9.22,"prevYearClose":5.305,"prevWeekClose":8,"prevMonthClose":7.85,"prevQuarterClose":6.9,"fiveDayClose":8,"twentyDayClose":5.67,"sixtyDayClose":5.48},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAGE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533960720","title":"Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2533960720","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533960720?lang=en_us&edition=fundamental","pubTime":"2025-05-08 05:41","pubTimestamp":1746654089,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc reports results for the quarter ended March 31 - Earnings SummaryNiagen Bioscience Inc NAGE.OQ reported quarterly adjusted earnings of 6 cents per share for the quarter ended Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL8N3RF3E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"1132614490","title":"Stock Track | Niagen Bioscience (NAGE) Soars 6.39% After-Hours on Strong Q1 Earnings, Raised Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1132614490","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132614490?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:50","pubTimestamp":1746651032,"startTime":"0","endTime":"0","summary":"Shares of Niagen Bioscience  surged 6.39% in after-hours trading following the release of its impressive first-quarter 2025 financial results. The company, which specializes in NAD+ precursor products for healthy aging, reported significant growth across key financial metrics and raised its full-year outlook, sparking investor enthusiasm.Adding to the positive sentiment, Niagen Bioscience raised its full-year 2025 outlook, projecting net sales growth between 20% and 25%, up from its previous est","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"1170170076","title":"Stock Track | Niagen Bioscience Soars 6.39% After Hours on Strong Q1 Results and Raised 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1170170076","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170170076?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:50","pubTimestamp":1746651031,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  stock surged 6.39% in after-hours trading on Wednesday, following the release of its impressive first-quarter 2025 financial results and an increased full-year outlook. The company, which specializes in NAD+ precursors and healthy aging solutions, reported significant growth across key financial metrics, surpassing analyst expectations.Adding to the positive sentiment, Niagen Bioscience raised its full-year 2025 outlook, projecting net sales growth between 20% and 25%, up from","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Niagen Bioscience Soars 6.39% After Hours on Strong Q1 Results and Raised 2025 Outlook","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NAGE"],"gpt_icon":0},{"id":"2533696988","title":"Niagen Bioscience Q1 EPS $0.06 Beats $0.02 Estimate, Sales $30.48M Beat $27.10M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533696988","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533696988?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:10","pubTimestamp":1746648646,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. This is a 700 percent increase over losses of $(0.01) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45266239/niagen-bioscience-q1-eps-0-06-beats-0-02-estimate-sales-30-48m-beat-27-10m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2533496284","title":"Niagen Bioscience Inc Outlook 2025 Company Expects Between 20% to 25% Year-Over-Year Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2533496284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533496284?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:02","pubTimestamp":1746648120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA287Q80:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2533650509","title":"Press Release: Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2533650509","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533650509?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:02","pubTimestamp":1746648120,"startTime":"0","endTime":"0","summary":"Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook.Niagen Bioscience, Inc.  today announced financial results for the first quarter of 2025.First Quarter 2025 Financial and Recent Operational Highlights. -- Total net sales were $30.5 million, with $21.5 million from Tru Niagen,up 38%, and 24%, respectively, from the prior year quarter.-- Total Niagen ingredient sales, including food-grade and. -- Sales and marketing expense as a percentage of net sales was 26.6%, an. improvement of 380 basis points, compared to 30.4% from the prior year. improvement of $5.6 million and $0.08 per share from the prior year. -- The Company announced its corporate name change to Niagen Bioscience,in healthy aging through its flagship ingredient, Niagen, reinforcing. its renewed mission: \"There's a better way to age.\". -- O","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4232","R","BK4022","NAGE"],"gpt_icon":0},{"id":"2533568979","title":"Niagen Bioscience Inc  expected to post earnings of 2 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533568979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533568979?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:20","pubTimestamp":1746476423,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc  expected to post earnings of2cents a share - Earnings Preview Niagen Bioscience Inc NAGE.OQ NAGE.O is expected to show a rise in quarterly revenue when it reports  results on Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD28M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2533890745","title":"Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2533890745","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533890745?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:32","pubTimestamp":1746448320,"startTime":"0","endTime":"0","summary":"Outperforming NAD+ IV, Niagen IV  provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion. Rob Fried, CEO of Niagen Bioscience, stated, \"At the heart of the Niagen Plus ecosystem are our sterile pharmaceutical-grade Niagen NR formulations for IV as well as intramuscular  and subcutaneous  injections. These Niagen NR products are high-quality solutions for those seeking the most advanced, clinically supported NAD-boosting interventions.\". Outperforming NAD+ IV, Niagen IV is a significant advancement in NAD-boosting therapy. In a head-to-head comparison with NAD+ IV, Niagen IV offers superior tolerability, a 75% shorter infusion time, and a statistically significant 20% increase in whole blood NAD+ levels three hours after infusion, as measured by NAD+ dried blood spot tests . Study results demonstrated that NAD+ IV had a longer infusion time and was associated with a high prevalence of uncomfortable side effects such as headac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/niagen-bioscience-announces-pharmaceutical-grade-123200413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2532878675","title":"Three High Growth Companies Insiders Are Eager To Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2532878675","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532878675?lang=en_us&edition=fundamental","pubTime":"2025-05-03 01:35","pubTimestamp":1746207333,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences a surge, with the S&P 500 on track for its longest winning streak since 2004, investors are closely watching growth companies that insiders are eager to hold onto. In such a buoyant market environment, stocks with high insider ownership can signal confidence in their future prospects and stability amidst economic uncertainties.Top 10 Growth Companies With High Insider Ownership In The United States. Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products with a market cap of $611.65 million.Click here to discover the nuances of Niagen Bioscience with our detailed analytical future growth report.The analysis detailed in our Niagen Bioscience valuation report hints at an inflated share price compared to its estimated value.Westrock Coffee's revenue growth is projected at 17.4% annually, surpassing the US market average. The company is expected to achieve profitabili","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/three-high-growth-companies-insiders-173533606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["WEST","TRVG","BK4196","BK4113","NAGE","HIMS","TBBB","BK4077"],"gpt_icon":1},{"id":"2531735417","title":"BRIEF-Niagen Bioscience Welcomes Pinchas Cohen To Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735417","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531735417?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:36","pubTimestamp":1745930189,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Welcomes Pinchas Cohen To Scientific Advisory BoardApril 29 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE WELCOMES DR. PINCHAS COHEN TO SCIENTIFIC ADVISORY BOARDSource text: ID:nBw1JpzDdaFurther company coverage: NAGE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA4V7ZSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2531973539","title":"Niagen Bioscience Welcomes DR. Pinchas Cohen to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531973539","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531973539?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:32","pubTimestamp":1745929920,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA4V7ZSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2531319297","title":"Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2531319297","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531319297?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:32","pubTimestamp":1745929920,"startTime":"0","endTime":"0","summary":"Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience’s commitment to advancing cutting-edge NAD+ and healthspan research. LOS ANGELES, April 29, 2025----Niagen Bioscience, Inc.  , the global authority on NAD+  with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board .Rob Fried, CEO of Niagen Bioscience, remarked, \"We are excited to learn from one of the great minds in mitochondrial and longevity research.\". Dr. Cohen expressed enthusiasm about the role, noting, \"I am honored to join Niagen Bioscience's Scientific Advisory Board. The company's commitment to rigorous scientific research in the field of NAD+ and its impact on aging and metabolic health is truly commendable. I look forward to contributing to their ongoing efforts to enhance healthspan through innovative approaches.\". Niagen Bioscience remains dedicated to collaborating with leading scientists to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/niagen-bioscience-welcomes-dr-pinchas-123200925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2530457404","title":"Press Release: Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530457404","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530457404?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:36","pubTimestamp":1745843760,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc.  , the global authority on NAD+  with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 7, 2025.Webcast link: Niagen Bioscience First Quarter 2025 Earnings Conference Call. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.Distinguished by state-of-the-art laboratories, rigorous scientific and quality prot","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","03160","BK4121","BK4555","BK4585","NAGE","BK4588","TM","BK4232","R","BK4022","BK4604"],"gpt_icon":0},{"id":"2525899360","title":"Niagen Bioscience Price Target Maintained With a $11.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899360","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899360?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:02","pubTimestamp":1744113720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2025 08:02 ET (12:02 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"gpt_icon":0},{"id":"2525886046","title":"BRIEF-Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2525886046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525886046?lang=en_us&edition=fundamental","pubTime":"2025-04-08 10:33","pubTimestamp":1744079587,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Confirms Its Operations Remain Unaffected By New TariffsApril 7 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE CONFIRMS ITS OPERATIONS REMAIN UNAFFECTED BY NEW TARI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QL0XB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2525090886","title":"Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2525090886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525090886?lang=en_us&edition=fundamental","pubTime":"2025-04-08 10:32","pubTimestamp":1744079553,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QL0XB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2525704136","title":"Niagen Says Its Operations Remain Resilient Amid Recent Tariff Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2525704136","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525704136?lang=en_us&edition=fundamental","pubTime":"2025-04-07 21:59","pubTimestamp":1744034395,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  said Monday that it does not expect global tariffs to disrupt its ability to manufacture food- and pharmaceutical-grade Niagen products, nor will they have an adverse impact on its ability to maintain costs and pricing.The company said all of its vitamins and food supplements are manufactured in the US by privately held specialty chemicals company WR Grace and are tested, bottled and packaged domestically. It also said only a small percentage of its raw materials are sourced internationally, which keeps costs relatively stable in the face of global price volatility.Foreign sales accounted for 24% of Niagen's revenue last year, with half of that coming from AS Watson in Hong Kong, which remains a duty-free market, the company said.Niagen chief executive officer Rob Fried said the company had previously decided to establish a US-based supply chain to ensure long-term resilience and quality.Niagen shares were more than 6% lower soon after Monday's opening bell.Price: 5.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAGE","BK4121"],"gpt_icon":0},{"id":"2525010753","title":"Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2525010753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525010753?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:32","pubTimestamp":1744029129,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL05F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2525704853","title":"Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2525704853","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525704853?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:32","pubTimestamp":1744029120,"startTime":"0","endTime":"0","summary":"The Company’s flagship patented nicotinamide riboside  ingredient, Niagen, is manufactured, encapsulated, and bottled in the U.S. and is currently classified as exempt from tariffs, minimizing exposure to tariff-related risks. LOS ANGELES, April 07, 2025----Niagen Bioscience, Inc.  , the global authority on NAD+  with a focus on the science of healthy aging, reaffirms that the manufacturing of its Niagen ingredient  and Tru Niagen and pharmaceutical-grade Niagen products remain resilient amid the recently enacted global tariffs.Manufactured in the U.S. by the Company’s partner, W.R. Grace, Niagen is rigorously tested, encapsulated, bottled, and packaged domestically as Tru Niagen using premium materials. With only a small percentage of materials sourced internationally, the cost to manufacture final Niagen products remains largely insulated from global price volatility.\"We made the decision to build a U.S.-based supply chain for Niagen to safeguard long-term resilience, trust, and qual","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/niagen-bioscience-confirms-operations-remain-123200897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","NAGE"],"gpt_icon":0},{"id":"2524961892","title":"Growth Companies With High Insider Ownership For April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524961892","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524961892?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:06","pubTimestamp":1743699986,"startTime":"0","endTime":"0","summary":"As the U.S. market grapples with the impact of newly announced tariffs, resulting in a sharp decline across major indices like the Dow Jones and Nasdaq, investors are increasingly focused on how these measures might affect economic growth and corporate profits. In such volatile conditions, companies with strong insider ownership often attract attention as they can indicate confidence from those who know the business best; this article highlights three growth companies in the United States where insiders hold significant stakes.Top 10 Growth Companies With High Insider Ownership In The United States. Delve into the full analysis future growth report here for a deeper understanding of Niagen Bioscience.Our comprehensive valuation report raises the possibility that Niagen Bioscience is priced higher than what may be justified by its financials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/growth-companies-high-insider-ownership-170626368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXFY","BK4539","TBBB","BWMN","BK4129","BK4023","NAGE","BK4113","BK4196"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"NAGE","fiscalQuarterEnding":"2025/03","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-03-04","symbol":"NAGE","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741064400000,"reportTimeType":"post","actualEps":0.03},{"market":"US","date":"2024-10-31","symbol":"NAGE","fiscalQuarterEnding":"2024/09","expectedEps":0.01,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730347200000,"reportTimeType":"post","actualEps":0.02},{"market":"US","date":"2024-08-07","symbol":"NAGE","fiscalQuarterEnding":"2024/06","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2024-05-08","symbol":"NAGE","fiscalQuarterEnding":"2024/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"post","actualEps":-0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1723262400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAGE","date":"2025-05-09","current":51.710369,"percent":0.085714,"low":49.393282,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"high":80.324484,"avg":64.248034,"sd":7.85779,"marketCap":729374756},"quantilePoints":[{"date":"2025-03-21","current":69.624479,"twenty":69.806742,"median":70.080136,"eighty":70.353531,"marketCap":595289295},{"date":"2025-03-28","current":67.346191,"twenty":68.676711,"median":69.624479,"eighty":70.371757,"marketCap":575809933},{"date":"2025-04-04","current":60.420196,"twenty":62.662031,"median":67.938546,"eighty":69.697384,"marketCap":516592673},{"date":"2025-04-11","current":51.67157,"twenty":54.861173,"median":62.880747,"eighty":69.551574,"marketCap":441791924},{"date":"2025-04-17","current":59.600012,"twenty":54.815607,"median":61.696037,"eighty":69.259953,"marketCap":509580103},{"date":"2025-04-25","current":67.255059,"twenty":55.043436,"median":62.151694,"eighty":68.530901,"marketCap":575030758},{"date":"2025-05-02","current":68.895427,"twenty":55.954751,"median":62.880747,"eighty":69.442216,"marketCap":589055899},{"date":"2025-05-09","current":51.710369,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"marketCap":729374756}],"updateTime":1746873717577}}}